Financings

Anacor Pharmaceuticals Inc. grossed $76.9 million in its recent IPO and private placement, including overallotment.

BioSante Pharmaceuticals Inc. is raising $18 million through a registered direct offering of stock and warrants.

Longwood Founders Management LLC closed an $85 million biotech venture capital fund.

Provectus Pharmaceuticals Inc. set up a $30 million committed equity financing facility.

Supernus Pharmaceuticals Inc. filed to raise $100 million in its initial public offering.

YM BioSciences Inc. grossed $46 million in its recent public offering, including overallotment.

Deals

Pathfinder LLC went public via a reverse merger with SyntheMed Inc. and will focus on cell therapy.

Sucampo Pharmaceuticals Inc. acquired patent-holding company Sucampo AG for $80 million.

. . . And More

Alimera Sciences Inc. and pSivida Corp. got an FDA complete response letter for Iluvien (fluocinolone acetonide intravitreal insert) in diabetic macular edema.

Cephalon Inc. dumped jet lag plans for Nuvigil (armodafinil) after a second complete response letter.

Endo Pharmaceuticals Inc. received FDA approval of Fortesta (testosterone 2% gel) for low testosterone.

Gilead Sciences Inc. halted Phase III work on Letairis (ambrisentan) in idiopathic pulmonary fibrosis.

MannKind Corp.'s PDUFA date for inhaled insulin drug Afrezza was extended by four weeks.